National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Review of the Analytical Model." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
97
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

Steps in the Calculation of Anticipated Health Benefits from Vaccine Use

The calculation of health benefits from vaccine use for each condition under study is a multistep process. The steps are listed in Box 5–1 and are described in the sections that follow.

Develop Morbidity Scenarios

For each condition studied, the committee, with the advice of outside experts, developed morbidity scenarios to describe the characteristic sequences of acute or chronic health states, the duration of each health state, and the proportion of persons with the condition who experience each scenario. The scenarios also capture the premature mortality associated with a condition but which is delayed 1 or more years beyond the onset of the condition. For most of the conditions included in the committee’s analysis, several scenarios were required to depict the associated morbidity.

Some pathogens or conditions affect specific subpopulations in distinctive ways. For example, the consequences of infection with chlamydia, a sexually transmitted disease, are very different in men and women. For those conditions, separate morbidity scenarios were defined for each appropriate subpopulation. The subpopulation analyses were combined in the final stages of the calculation of the cost-effectiveness ratio.

Calculate Quality-Adjustment Weights

Once the morbidity scenarios were developed, the committee reviewed each health state and assigned a level in each of the seven attributes of HUI Mark II. To better reflect the range of morbidity represented by some health states, the committee estimated the proportion of cases of illness that should be assigned to each level of a specific health utility attribute. The preference score for the attri bute was calculated as a weighted average of the scores for each level. The quality-adjustment weight for the health state was obtained by combining the scores for each attribute according to Equation 4. The calculations were performed using an Excel spreadsheet template.

Calculate Discounted Quality-Adjusted Life Expectancies

The quality-adjustment weights for each condition’s morbidity scenarios (described above) were used to measure QALYs without the vaccine intervention. Quality-adjustment weights reflecting the average health status of the

Page
97
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)